Peking Union Medical College
pumc.edu.cnMatched: Peking Union Medical College Hospital · Peking Union Medical College
Live pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,177
Active
362
Phase 3
68
Total enrollment
1,212,424
Pipeline matrix
Showing 40 of 264 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Chemotherapy | — | — | 8 | ||||
| Rituximab | — | — | — | 10 | |||
| Traditional Chinese Medicine | — | — | — | — | 3 | ||
| Aspirin | — | — | — | 8 | |||
| rhTPO | — | — | — | — | 3 | ||
| Romiplostim | — | — | — | — | — | 3 | |
| Western medicine | — | — | — | — | 2 | ||
| Cyclosporin A | — | — | — | — | 2 | ||
| Clopidogrel | — | — | — | 4 | |||
| Anlotinib | — | — | — | — | 3 | ||
| Carboplatin or Cisplatin | — | — | — | — | 2 | ||
| Belimumab | — | — | — | — | — | 2 | |
| Etoposide | — | — | — | — | 2 | ||
| Berberine | — | — | — | — | 2 | ||
| Statin | — | — | — | — | 2 | ||
| Semaglutide | — | — | — | — | — | 1 | |
| Traditional Chinese Medicine Formulation | — | — | — | — | — | 1 | |
| intravenous ondansetron | — | — | — | — | — | 1 | |
| ondansetron and dyclonine hydrochloride | — | — | — | — | — | 1 | |
| dyclonine hydrochloride only | — | — | — | — | — | 1 | |
| Indomethacin SR | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| Rosuvastatin | — | — | — | — | — | 1 | |
| Ezetimibe | — | — | — | — | — | 1 | |
| Recaticimab | — | — | — | — | — | 1 | |
| Benmelstobart | — | — | — | — | — | 1 | |
| Tegileridine | — | — | — | — | — | 1 | |
| morphine | — | — | — | — | — | 1 | |
| Compound sodium acetate ringer | — | — | — | — | — | 1 | |
| Albumin | — | — | — | — | — | 1 | |
| Janus Kinase Inhibitor | — | — | — | — | — | 1 | |
| Adalimumab plus different doses of oral glucocorticosteroid | — | — | — | — | — | 1 | |
| Recaticimab and Statin | — | — | — | — | — | 1 | |
| Ferric derisomaltose | — | — | — | — | — | 1 | |
| Ferrous succinate | — | — | — | — | — | 1 | |
| Standard treatment | — | — | — | — | — | 1 | |
| Oral ondansetron and dyclonine hydrochloride mucilage | — | — | — | — | — | 1 | |
| Dyclonine hydrochloride mucilage | — | — | — | — | — | 1 | |
| Isatuximab, bortezomib, lenalidomide, dexamethason | — | — | — | — | — | 1 | |
| Bortezomib, Lenalidomide, Dexamethasone | — | — | — | — | — | 1 |
224 more active programs hidden
Next readouts
- 2023-12-08
- 2024-02-02
- 2024-09-05
- 2024-10-01
- 2024-10-23
- 2024-11-13
- 2024-12-31
- 2024-12-31
- 2025-01
- 2025-01-01
Top conditions
- Breast Cancer45
- Pancreatic Cancer18
- Hepatocellular Carcinoma15
- Cervical Cancer15
- Aplastic Anemia15
- Lung Cancer13
- Surgery11
- Stroke11
Frequently asked questions about Peking Union Medical College
- How many clinical trials does Peking Union Medical College have on ClinicalTrials.gov?
- Peking Union Medical College is listed as the lead sponsor on 1,177 clinical trials in ClinicalTrials.gov, 362 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Peking Union Medical College's trials are in Phase 3?
- 68 of Peking Union Medical College's trials are in Phase 3, spread across 264 active drug programs.
- What therapeutic areas does Peking Union Medical College focus on?
- Peking Union Medical College's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Cervical Cancer, Aplastic Anemia.
- When are Peking Union Medical College's next clinical trial readouts?
- Peking Union Medical College has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy”, expected around 2023-12-08.